@CARTTherapy

Cellular & Gene Therapy Program @ KFSHRC KSA #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy

Joined December 2019
  • Tweets4.4K
  • Following76
  • Followers4.6K
1.2KMedia
Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS ashpublications.org/blood/ar…
3
279
Genomic and clinical landscape of RAS mutations in acute myeloid leukemia ashpublications.org/blood/ar…

Genomic and clinical landscape of RAS mutations in acute myeloid leukemia

Key Points. RAS mutations exhibit epistatic constraints shaping co-mutational profiles, with frequent evolutionary convergence of multiple RAS mutationsRAS

ashpublications.org
3
508
MDM4 haploinsufficiency leads to p53-mediated bone marrow failure ashpublications.org/blood/ar…

MDM4 haploinsufficiency leads to p53-mediated bone marrow failure

Key PointsGerm line heterozygous loss-of-function MDM4 variants cause variable hematologic phenotypes with hypocellular bone marrow and cytopenia.Mechanist

ashpublications.org
172
A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years ashpublications.org/blood/ar…

A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly...

Key Points. Midostaurin after LDAC and venetoclax is deliverable but did not improve outcomes in older patients with non-adverse cytogenetic risk AMLIn FLT

ashpublications.org
4
340
Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
4
7
566
Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
3
4
389
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…
2
190
First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…
2
5
617
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx retweeted
NEJM
@NEJMSep 23
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.

3
52
5
115
35,057
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma | NEJM

Anitocabtagene autoleucel (anito-cel), a B-cell maturation antigen (BCMA)–directed autologous chimeric antigen receptor (CAR) T-cell therapy with a synthetic d-domain binder (ddBCMA), may have effi...

nejm.org
1
1
336
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma | NEJM

Anitocabtagene autoleucel (anito-cel), a B-cell maturation antigen (BCMA)–directed autologous chimeric antigen receptor (CAR) T-cell therapy with a synthetic d-domain binder (ddBCMA), may have effi...

nejm.org
1
3
582
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx retweeted
Binod Dhakal@bhematoSep 24
Phase I results of Anito-cel and d-domain story published in NEJM! Exciting results and very delighted to be a part of this study @MedicalCollege @MCWCancerC2u8v
NEJM
@NEJMSep 23
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.

2
9
44
4,334
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study - The Lancet Haematology thelancet.com/journals/lanha…
8
14
1,535
Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial - The Lancet Haematology thelancet.com/journals/lanha…

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results...

The addition of venetoclax to DA-EPOCH-R resulted in excess mortality, prompting early study closure. Robust accrual shows that prospective multicentre trials are feasible in double-hit lymphoma, and...

thelancet.com
8
30
2,280
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx retweeted
Benlazar S M A@smbenlazarAug 13
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease ashpublications.org/blood/ar… #mmsm
10
23
1,669
Survodutide Once Weekly for the Treatment of Adults with Obesity | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Survodutide Once Weekly for the Treatment of Adults with Obesity | NEJM

Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain. Su...

nejm.org
1
347
Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic...

PURPOSEThe clinical efficacies of third- or later-line therapies for metastatic colorectal cancer (CRC) are extremely limited. The purpose of this study was to evaluate the safety and efficacy of a...

ascopubs.org
3
377
Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy | NEJM

HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desens...

nejm.org
1
7
1,061
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx retweeted
NEJM
@NEJMJun 8
Original Article: All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia (ASCERTAIN-V trial) nej.md/4fpoGzl #Hematology
This image contains a multi-section figure related to dose adjustments for a study. Section A is a flowchart titled "Recommended Approach to Dose Adjustments for Phase 2b." Section B is a graph showing the percentage of patients who received venetoclax for 28 days across cycles 1 to 4 in Phase 1, Phase 2a, and Phase 2b. Section C presents a graph displaying the percentage of patients who received DEC-C for 5 days over the same cycles and phases.

ALT This image contains a multi-section figure related to dose adjustments for a study. Section A is a flowchart titled "Recommended Approach to Dose Adjustments for Phase 2b." Section B is a graph showing the percentage of patients who received venetoclax for 28 days across cycles 1 to 4 in Phase 1, Phase 2a, and Phase 2b. Section C presents a graph displaying the percentage of patients who received DEC-C for 5 days over the same cycles and phases.

Survival curve graph depicting the percentage of patients surviving over 42 months across three study phases: Phase 1, Phase 2a, and Phase 2b. Phases 2a and 2b have separate lines. Median overall survival is noted, with Phase 1 at 6.8 months, Phase 2a at 14.5 months, and Phase 2b at 17.5 months. A table below shows the number of patients at risk for each phase.

ALT Survival curve graph depicting the percentage of patients surviving over 42 months across three study phases: Phase 1, Phase 2a, and Phase 2b. Phases 2a and 2b have separate lines. Median overall survival is noted, with Phase 1 at 6.8 months, Phase 2a at 14.5 months, and Phase 2b at 17.5 months. A table below shows the number of patients at risk for each phase.

1
11
61
16,095
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia ashpublications.org/blood/ar…

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid...

Next-generation sequencing (NGS) FLT3-internal tandem duplication (ITD) measurable residual disease (MRD) testing for patients in remission from acute myel

ashpublications.org
5
966
Load more